Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay)
07:30am - 03:45pm EDT - April 1, 2023
07:30am - 03:45pm EDT - April 1, 2023
Author(s):
- Dr. Miao Jiang, PhD, Director, Real World Evidence, Adaptive Biotechnologies Corporation
Tags: Outcomes and Health Services Research
| Display Label | Action |
|---|---|
| 2023 NCCN Annual Meeting Poster_submitted.pdf | Download Handout |
| AC23P129 - Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay) | Download MP3 |
